EUVIMEDEUVIMED entdecken
Crossref

Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation

Shigeo Fuji iD, Akihiro Ohmoto iD, Yuho Najima iD, Kazuki Yoshimura, Naoyuki Uchida, Masatsugu Tanaka, Yuta Hasegawa, Takahiro Fukuda, Noboru Asada, Masashi Sawa, Mamiko Sakata-Yanagimoto, Masataka Ishimura iD und 8 weitere

British Journal of Haematology · 2026-06 · 208 (6) · 2168-2174

DOI: 10.1111/bjh.70450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 22.03.2026. Verfasst von Shigeo Fuji und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Immunosuppressive Agents, Immunosuppression Therapy. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Research on Transplant Medicine of the Ministry of Health, Labour and Welfare of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical impact of immunosuppression termination (IST) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) remains to be fully elucidated. This study was aimed at assessing the impact of IST within 2 years after transplantation on subsequent clinical outcomes. We analysed data for patients from the Transplant Registry Unified Management Program 2 (TRUMP 2) database who survived without progression for at least 2 years after allo‐HSCT. Of the 5061 patients whose median age was 48 (range: 0–79) years, 2320 discontinued immunosuppressive therapy within 2 years (IST group), while 2741 did not (non‐IST group). The 4‐year overall survival (OS) rate was significantly higher in the IST group than in the non‐IST group (95.3% vs. 90.8%; p < 0.01). The 4‐year cumulative incidence of non‐relapse mortality (NRM) was significantly lower in the IST group than in the non‐IST group (3.5% vs. 8.6%; p < 0.01). This reduction in NRM was consistent across major causes, including graft‐versus‐host disease (GVHD)‐related mortality, infection‐related mortality and organ failure‐related mortality. Immunosuppressive therapy beyond 2 years after allo‐HSCT was associated with inferior OS. Our findings suggest that the optimal transplant strategy is necessary to avoid long‐term immunosuppression for improving clinical outcomes in allo‐HSCT recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationImmunosuppressive AgentsImmunosuppression TherapyHumansMiddle AgedFemaleAdultMaleAdolescentAgedTransplantation, HomologousChild, PreschoolYoung AdultChildGraft vs Host DiseaseInfantRegistriesTreatment Outcome

Stichwörter der Autor:innen

allogeneic haematopoietic stem cell transplantationimmunosuppressive drugsurvivorship

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
  • Advanced Medical Development Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
  • Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Shigeo Fuji, Akihiro Ohmoto, Yuho Najima, Masataka Ishimura, Makoto Onizuka

Förderung

  • Research on Transplant Medicine of the Ministry of Health, Labour and Welfare of Japan

Zitieren

APA

Fuji, S., Ohmoto, A., Najima, Y., Yoshimura, K., Uchida, N., Tanaka, M., Hasegawa, Y., Fukuda, T., Asada, N., Sawa, M., Sakata-Yanagimoto, M., Ishimura, M., Onizuka, M., Nishida, T., Doki, N., Kawamura, K., Hino, M., Kanda, Y., Atsuta, Y., & Yakushijin, K. (2026). Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 208(6), 2168-2174. https://doi.org/10.1111/bjh.70450

Vancouver

Fuji S, Ohmoto A, Najima Y, Yoshimura K, Uchida N, Tanaka M, et al. Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2026;208(6):2168-2174. doi:10.1111/bjh.70450

BibTeX
@article{Fuji2026,
  author = {Fuji, Shigeo and Ohmoto, Akihiro and Najima, Yuho and Yoshimura, Kazuki and Uchida, Naoyuki and Tanaka, Masatsugu and Hasegawa, Yuta and Fukuda, Takahiro and Asada, Noboru and Sawa, Masashi and Sakata-Yanagimoto, Mamiko and Ishimura, Masataka and Onizuka, Makoto and Nishida, Tetsuya and Doki, Noriko and Kawamura, Koji and Hino, Moeko and Kanda, Yoshinobu and Atsuta, Yoshiko and Yakushijin, Kimikazu},
  title = {Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {6},
  pages = {2168--2174},
  doi = {10.1111/bjh.70450}
}
Kostenlos starten →